24 patents
Utility
Tgfbeta Signal Convertor
16 Nov 23
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Benjamin BOYERINAS
Filed: 7 Apr 23
Utility
TCRa HOMING ENDONUCLEASE VARIANTS
9 Nov 23
The present disclosure provides improved genome editing compositions and methods for editing a TCRα gene.
Jordan JARJOUR, Mark POGSON
Filed: 24 Feb 23
Utility
Bcma Chimeric Antigen Receptors
5 Oct 23
The disclosure provides improved compositions for adoptive T cell therapies for B cell related conditions.
SHANNON GRANDE CONTRASTANO, EMILY G. KUIPER
Filed: 24 Aug 21
Utility
Multipartite Signaling Proteins and Uses Thereof
14 Sep 23
The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
Jordan Jarjour, Alexander Astrakhan, Michael Certo
Filed: 10 Nov 22
Utility
Methods for Manufacturing Viral Vectors
6 Jul 23
The present disclosure provides improved systems and methods for purifying and/or concentrating lentiviral compositions.
BRENT JULIAN COISMAN
Filed: 10 Jun 21
Utility
Mage A4 T Cell Receptors
25 May 23
The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR.
Christian ELLINGER, Daniel SOMMERMEYER, Geoffrey PARSONS, Jasdeep MANN
Filed: 27 Mar 20
Utility
FRB Antibodies
18 May 23
The invention provides anti-FRB antibodies or antigen binding fragments thereof that bind an FRB polypeptide.
ALEXANDER ASTRAKHAN
Filed: 9 Apr 21
Utility
T Cell Receptors
20 Apr 23
The present disclosure provides improved T cell receptors, polynucleotides, polypeptides, vectors, cells, and methods f using the same.
JASDEEP MANN
Filed: 26 Mar 21
Utility
Engineered T Cells
9 Feb 23
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JASDEEP MANN, CHRISTIAN ELLINGER, DANIEL SOMMERMEYER, BENJAMIN BOYERINAS
Filed: 7 May 20
Utility
Anti-bcma Car Antibodies, Conjugates, and Methods of Use
2 Feb 23
The invention provides improved methods for detecting anti-BCMA CAR expression on T cells.
KEVIN FRIEDMAN, MOLLY REED PERKINS
Filed: 16 Dec 20
Utility
Dimerizing Agent Regulated Immunoreceptor Complexes
2 Feb 23
The present disclosure provides adoptive T cell therapies that have improved DARIC architectures for targeting tumor antigens and recruiting TCR signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JORDAN JARJOUR, ALEXANDER ASTRAKHAN, WAI-HANG LEUNG
Filed: 30 Sep 20
Utility
Adoptive Cell Therapy
17 Nov 22
The invention provides improved methods for adoptive cell therapies for the treatment of cancer.
JAMES BRIAN ROTTMAN
Filed: 20 Mar 20
Utility
PD-1 Homing Endonuclease Variants, Compositions, and Methods of Use
27 Oct 22
The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene.
Jasdeep MANN, Joel GAY, Jordan JARJOUR, Joy ZHANG
Filed: 6 May 22
Utility
CLL-1 Targeted Immunotherapies
13 Oct 22
The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, LUCAS RASCON, ANGELICA SANABRIA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
Filed: 7 May 20
Utility
CD33 Targeted Immunotherapies
13 Oct 22
The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, KYLE JONES, WILLIAM CRAGO, ANGELICA SANABRIA, ANDREW HOLLANDS, JACOB GANO, MILTON MA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
Filed: 7 May 20
Utility
CD123 Targeted Immunotherapies
6 Oct 22
The present disclosure provides improved CD123 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, CHELSIE MACEDO, KYLE JONES, WILLIAM CRAGO, ANDREW HOLLANDS, MILTON MA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
Filed: 7 May 20
Utility
Compositions and Methods for Treating Cancer
8 Sep 22
The invention provides improved compositions for adoptive cell therapies for cancers that express CD79A and/or CD20.
KEVIN FRIEDMAN
Filed: 11 Jun 20
Utility
CD79B Chimeric Antigen Receptors
21 Jul 22
The invention provides improved compositions for adoptive cell therapies for cancers that express CD79B.
Kevin FRIEDMAN, Molly Reed PERKINS
Filed: 14 Jun 19
Utility
Multivalent Chimeric Antigen Receptor
14 Jul 22
The invention provides improved chimeric antigen receptors, polynucleotides, polypeptides, compositions thereof, and methods of making and using the same for adoptive cell therapies for cancers.
MARK POGSON
Filed: 21 Dec 18
Utility
Salvage Chimeric Antigen Receptor Systems
23 Jun 22
The invention provides improved compositions for adoptive cell therapies for cancers.
Wai-Hang LEUNG
Filed: 14 Apr 17